var data={"title":"Chagas disease in the immunosuppressed host","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chagas disease in the immunosuppressed host</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/contributors\" class=\"contributor contributor_credentials\">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 06, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H944109389\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi</em>; the major manifestations are Chagas cardiomyopathy and gastrointestinal disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Issues related to Chagas in the setting of immunosuppression are reviewed here. Issues relating to acute and chronic Chagas infection are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;</a> and <a href=\"topic.htm?path=chagas-disease-chronic-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Chronic Trypanosoma cruzi infection&quot;</a>.)</p><p>Issues related to epidemiology and prevention of Chagas disease are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention\" class=\"medical medical_review\">&quot;Chagas disease: Epidemiology and prevention&quot;</a>.)</p><p>Issues related to cardiac and gastrointestinal Chagas are discussed separately. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;</a> and <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1365939822\"><span class=\"h1\">FORMS OF DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Forms of Chagas disease in immunosuppressed hosts include reactivation of <em>T. cruzi</em> infection (in HIV-infected patients and patients on immunosuppressive medications) and donor-derived infection in organ transplant recipients.</p><p class=\"headingAnchor\" id=\"H3802398010\"><span class=\"h2\">Reactivation of chronic Chagas in immunosuppressed patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactivation of preexisting chronic <em>T. cruzi</em> infection can occur in patients who become immunosuppressed due to HIV or administration of immunosuppressive medications (for solid organ or bone marrow transplantation) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Rarely, <em>T. cruzi</em> reactivation has been reported during chemotherapy for lymphoma or leukemia [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/4-6\" class=\"abstract_t\">4-6</a>].</p><p class=\"headingAnchor\" id=\"H1896463927\"><span class=\"h3\">Clinical manifestations</span></p><p class=\"headingAnchor\" id=\"H278374802\"><span class=\"h4\">HIV-infected patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactivation of <em>T. cruzi</em> infection can occur in the setting of <span class=\"nowrap\">HIV/AIDS,</span> usually when the CD4 count falls below 200 <span class=\"nowrap\">cells/microL,</span> and can cause severe disease with high risk of mortality. Reactivation is rare in <em>T. cruzi</em>&ndash;HIV coinfected patients who achieve immune reconstitution with antiretroviral therapy (ART).</p><p>In one series including 53 patients with HIV and <em>T. cruzi</em> infection followed for 1 to 190 months, <em>T. cruzi</em> reactivation was observed in 21 percent of patients; the diagnosis was established based on symptoms <span class=\"nowrap\">and/or</span> positive peripheral blood smear [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7\" class=\"abstract_t\">7</a>]. Even among patients without clinical manifestations of reactivation, the level of parasitemia is higher among HIV-infected patients than HIV-uninfected individuals [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/8\" class=\"abstract_t\">8</a>].</p><p>The most commonly reported manifestations of symptomatic <em>T. cruzi</em> reactivation in patients with AIDS are meningoencephalitis <span class=\"nowrap\">and/or</span> <em>T. cruzi</em> brain abscesses (chagomas) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7,9,10\" class=\"abstract_t\">7,9,10</a>]. The presentation may be confused with central nervous system (CNS) toxoplasmosis and should be considered in the differential diagnosis of patients with HIV infection and CNS symptoms or mass lesions on imaging (<a href=\"image.htm?imageKey=ID%2F82194\" class=\"graphic graphic_diagnosticimage graphicRef82194 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7,9-11\" class=\"abstract_t\">7,9-11</a>]. The most common appearance on imaging is that of one or more hypodense lesions [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p>The second most common reported manifestation of reactivation in <span class=\"nowrap\">HIV/AIDS</span> patients is acute myocarditis, sometimes superimposed on preexisting chronic Chagas heart disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7,12\" class=\"abstract_t\">7,12</a>]. Patients may present with new arrhythmias, pericardial effusions, acute cardiac decompensation, or accelerated progression of existing chronic cardiomyopathy [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7,13\" class=\"abstract_t\">7,13</a>].</p><p>Acute meningoencephalitis and myocarditis can occur simultaneously. In one Brazilian cohort, cardiac reactivation was as frequent as CNS disease; cardiac reactivation may be subtle and can mimic progression of chronic Chagas cardiomyopathy [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Other manifestations of Chagas reactivation in the setting of <span class=\"nowrap\">HIV/AIDS</span> include skin lesions, erythema nodosum, and parasitic invasion of the peritoneum, stomach, or intestine [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/8,13\" class=\"abstract_t\">8,13</a>].</p><p class=\"headingAnchor\" id=\"H2546020043\"><span class=\"h4\">Transplant recipients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transplant recipients with preexisting chronic <em>T. cruzi</em> infection can experience reactivation. Clinical manifestations include fever, myocarditis, symptoms suggestive of rejection, <span class=\"nowrap\">and/or</span> dermatologic manifestations, including inflammatory panniculitis and skin nodules [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/14-19\" class=\"abstract_t\">14-19</a>]. CNS involvement can occur in transplant recipients with reactivation but is less frequent than among patients with reactivation attributable to HIV infection [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/18,20,21\" class=\"abstract_t\">18,20,21</a>].</p><p>In one study of 23 renal transplant recipients in Argentina followed for up to seven years, five patients were diagnosed with reactivation based on parasitemia (21 percent) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19\" class=\"abstract_t\">19</a>]. Of these patients, two had skin lesions and one of these also had panniculitis; the other three patients were asymptomatic. Reactivation was diagnosed 35 to 97 days post-transplant in four of the five patients; the fifth had reactivation detected 29 months after transplantation. (See <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis#H3861828313\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;, section on 'Cardiac transplantation'</a>.)</p><p class=\"headingAnchor\" id=\"H1592432218\"><span class=\"h3\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactivated Chagas infection should be suspected in immunosuppressed individuals with relevant symptoms (CNS symptoms, myocarditis, <span class=\"nowrap\">and/or</span> skin lesions) with a history of prior exposure to areas of Latin America with vector-borne transmission of Chagas disease.</p><p>The approach to diagnosis of reactivated Chagas disease is similar to the approach to diagnosis of acute <em>T. cruzi</em> infection; tools include light microscopy of fresh whole blood or buffy coat for detection of circulating trypomastigotes and serum polymerase chain reaction (PCR) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7,22\" class=\"abstract_t\">7,22</a>]. However, a positive result by conventional PCR does not prove reactivation; rising parasite numbers by quantitative PCR in serial specimens provide the earliest indicator [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/23,24\" class=\"abstract_t\">23,24</a>]. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection#H2177685264\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;, section on 'Acute T. cruzi infection'</a>.)</p><p>Presence of skin lesions should prompt impression smears <span class=\"nowrap\">and/or</span> stained biopsy specimens to evaluate for presence of <em>T. cruzi</em> organisms in skin lesions [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/25,26\" class=\"abstract_t\">25,26</a>].</p><p class=\"headingAnchor\" id=\"H1494447060\"><span class=\"h3\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with chronic Chagas disease who undergo solid organ or bone marrow transplantation warrant monitoring for reactivation. There are no data to suggest that routine monitoring is indicated for HIV-infected patients [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/27\" class=\"abstract_t\">27</a>].</p><p>The approach to monitoring consists of testing blood samples (for microscopy and PCR) weekly for the first 2 months, twice monthly for the next month, then monthly up to 6 months. Subsequently, monitoring intervals can be lengthened [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28-30\" class=\"abstract_t\">28-30</a>]. In addition, interval specimens are warranted in the setting of febrile episodes and suspected rejection crises [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28,31\" class=\"abstract_t\">28,31</a>]. The monitoring schedule for heart transplant recipients can be coordinated with the monitoring schedule for rejection [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28,30,31\" class=\"abstract_t\">28,30,31</a>].</p><p>Laboratory testing should include microscopy of fresh whole blood or buffy coat for circulating trypomastigotes and quantitative PCR in peripheral blood. A positive result by conventional PCR does not prove reactivation, but rising parasite numbers by quantitative PCR in serial specimens provide the earliest indicator [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/23,24\" class=\"abstract_t\">23,24</a>]. In addition to laboratory testing, heart transplant recipients should have endomyocardial biopsy tissue specimens evaluated for histological demonstration of acute myocarditis in the transplanted heart [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/26,30\" class=\"abstract_t\">26,30</a>].</p><p class=\"headingAnchor\" id=\"H2323762035\"><span class=\"h2\">Donor-derived acute Chagas in organ transplant recipients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Organ transplant recipients who receive an organ from a donor infected with <em>T. cruzi</em> may develop acute <em>T. cruzi</em> infection, although transmission under these circumstances appears to be fairly uncommon. In series of 16 recipients of kidney transplants from infected donors, three acquired <em>T. cruzi</em> infection (19 percent) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19\" class=\"abstract_t\">19</a>]. More than 20 cases of Chagas disease transmission by solid organ transplantation have been documented in the literature (at least 15 kidney, 1 kidney and pancreas, 4 liver, 3 heart transplants) [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19,32-42\" class=\"abstract_t\">19,32-42</a>]. Hearts from known infected donors are never transplanted in Latin America; all such transplants have occurred in the United States from donors with unknown infection status at the time of the transplant [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/33,39,40\" class=\"abstract_t\">33,39,40</a>]. In one study, three of the four heart recipients became infected; based on these sparse data and the known tropism of the parasite, the transmission risk is likely higher for hearts than for other organs [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28,40\" class=\"abstract_t\">28,40</a>].</p><p class=\"headingAnchor\" id=\"H3101896265\"><span class=\"h3\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among the 10 organ recipients for whom data were available in published reports, the period from transplantation to onset of symptoms of acute <em>T. cruzi</em> infection ranged from 23 to 300 days (mean 103 days; median 62 days). Symptoms included fever, malaise, anorexia, hepatosplenomegaly, acute myocarditis, and decreased cardiac function. Two of the reported patients presented with fulminant myocarditis and congestive heart failure [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/32,42\" class=\"abstract_t\">32,42</a>].</p><p class=\"headingAnchor\" id=\"H3859670968\"><span class=\"h3\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ideally, donor-derived acute <em>T. cruzi</em> infection is detected via monitoring, prior to onset of symptoms. (See <a href=\"#H3373172918\" class=\"local\">'Monitoring'</a> below.)</p><p>The approach to diagnosis of donor-derived acute <em>T. cruzi</em> infection is the same as the approach to diagnosis of acute Chagas infection; tools include light microscopy of fresh whole blood or buffy coat for detection of circulating trypomastigotes and serum PCR. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection#H3331542074\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H3373172918\"><span class=\"h3\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Identification of donor infection following organ transplantation should prompt careful post-transplant monitoring of the recipients. Patients whose infection is detected early through monitoring have excellent response to treatment and good clinical outcomes [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19,39\" class=\"abstract_t\">19,39</a>].</p><p>Monitoring consists of evaluation for evidence of infection in the recipient by microscopy and PCR, if available. Microscopy should be performed on a fresh specimen in the first one to two hours after collection, when trypomastigotes are still motile and therefore more readily detected. PCR has the highest sensitivity but requires a specialized laboratory. In the United States, the Centers for Disease Control and Prevention (CDC) act as a reference laboratory for <em>T. cruzi</em> PCR (Division of Parasitic Diseases Public Inquiries line, 404-718-4745; for emergencies after business hours, 770-488-7100; email parasites@cdc.gov).</p><p>Monitoring should consist of weekly specimens for two months, every two weeks for the third month, and then monthly until six months post-transplantation, when the monitoring interval can be lengthened if no evidence of infection has been detected [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28\" class=\"abstract_t\">28</a>]. In the case of febrile episodes or suspected rejection, additional specimens should be evaluated [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19,40,41\" class=\"abstract_t\">19,40,41</a>].</p><p>Additional issues related to laboratory diagnosis of acute and chronic <em>T. cruzi </em>infection are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;</a> and <a href=\"topic.htm?path=chagas-disease-chronic-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Chronic Trypanosoma cruzi infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2256850938\"><span class=\"h1\">TREATMENT AND PREVENTION</span></p><p class=\"headingAnchor\" id=\"H2407026926\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to management of Chagas disease in immunocompromised patients and the efficacy of secondary prophylaxis remain uncertain [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/3,43\" class=\"abstract_t\">3,43</a>]. Data are limited to observational studies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among transplant patients with reactivated infection, treatment with <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> accelerated improvement in clinical symptoms and reduced intensity of parasitemia [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19-21,44\" class=\"abstract_t\">19-21,44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a small series of patients with HIV and <em>T. cruzi</em> coinfection, a course of <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> therapy resulted in improvement of clinical manifestations and decreased parasitemia [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p>In general, antitrypanosomal therapy is warranted for patients all with reactivated <em>T. cruzi</em> infection and for all patients with donor-derived acute <em>T. cruzi</em> infection (<a href=\"image.htm?imageKey=ID%2F65745\" class=\"graphic graphic_table graphicRef65745 \">table 1</a>). Antitrypansomal drugs include <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> and nifurtimox; in general, benznidazole is better tolerated so is favored as the first-line treatment for Chagas disease. Dosing and adverse effects are outlined in the tables (<a href=\"image.htm?imageKey=ID%2F54443\" class=\"graphic graphic_table graphicRef54443 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F67193\" class=\"graphic graphic_table graphicRef67193 \">table 3</a>). Issues related to antitrypanosomal drugs are discussed further separately. (See <a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">&quot;Chagas disease: Antitrypanosomal drug therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1793244921\"><span class=\"h2\">Prevention</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no role for routine presumptive antitrypanosomal treatment for patients at risk of reactivation (such as HIV-infected patients and patients with previously untreated <em>T. cruzi</em> infection awaiting organ transplant) or for prevention of donor-derived acute <em>T.</em> <em>cruzi</em> infection [<a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/3,28\" class=\"abstract_t\">3,28</a>].</p><p>Presumptive treatment is unlikely to be curative and carries substantial risk of adverse effects. In addition, establishing the presence of infection is important for long-term management; presumptive treatment would preclude this evaluation. Therefore, close monitoring is warranted as described above; detection of acute infection or reactivation should prompt initiation of treatment. (See <a href=\"#H1494447060\" class=\"local\">'Monitoring'</a> above and <a href=\"#H3373172918\" class=\"local\">'Monitoring'</a> above.)</p><p>In HIV-infected patients, optimization of antiretroviral therapy is the most important means of preventing <em>T. cruzi</em> reactivation. (See <a href=\"topic.htm?path=acute-and-early-hiv-infection-treatment\" class=\"medical medical_review\">&quot;Acute and early HIV infection: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H654269154\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3818210673\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reactivation of preexisting chronic <em>Trypanosoma cruzi</em> infection can occur in patients who become immunosuppressed due to HIV or immunosuppressive regimens for solid organ or bone marrow transplantation. Rarely, <em>T. cruzi</em> reactivation has been reported during chemotherapy for lymphoma or leukemia. (See <a href=\"#H3802398010\" class=\"local\">'Reactivation of chronic Chagas in immunosuppressed patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most commonly reported manifestations of symptomatic <em>T. cruzi</em> reactivation in patients with AIDS are meningoencephalitis <span class=\"nowrap\">and/or</span> <em>T. cruzi</em> brain abscesses (chagomas). The presentation may be confused with central nervous system (CNS) toxoplasmosis and should be considered in the differential diagnosis of patients with HIV infection and CNS symptoms or mass lesions on imaging. (See <a href=\"#H278374802\" class=\"local\">'HIV-infected patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations of <em>T. cruzi</em> reactivation among transplant recipients include fever, myocarditis, symptoms suggestive of rejection, <span class=\"nowrap\">and/or</span> dermatologic manifestations, including inflammatory panniculitis and skin nodules. CNS involvement can occur but is less frequent than among patients with reactivation attributable to HIV infection. (See <a href=\"#H2546020043\" class=\"local\">'Transplant recipients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of reactivation is confirmed by detection of circulating trypomastigotes in the peripheral blood; quantitative polymerase chain reaction (PCR) on serial specimens is a useful technique to show rising parasite load. A positive result on conventional PCR does not prove reactivation, but quantitative PCR assays that indicate rising parasite numbers over time provide the earliest and most sensitive indicator of reactivation. (See <a href=\"#H1592432218\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with chronic Chagas disease who undergo solid organ or bone marrow transplantation warrant monitoring for reactivation. There are no data to suggest that routine monitoring is indicated for HIV-infected patients. (See <a href=\"#H1494447060\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organ transplant recipients who receive an organ from a donor infected with <em>T. cruzi</em> may develop acute <em>T. cruzi</em> infection; transmission under these circumstances appears to be fairly uncommon. The period from transplantation to onset of symptoms of acute <em>T. cruzi</em> infection has ranged from 23 to 300 days (mean 103 days; median 62 days). Symptoms included fever, malaise, anorexia, hepatosplenomegaly, acute myocarditis, and decreased cardiac function. Two patients presented with fulminant myocarditis and congestive heart failure. (See <a href=\"#H3101896265\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Identification of donor infection following organ transplantation should prompt careful post-transplant monitoring of the recipients. The approach to monitoring consists of testing blood samples (for microscopy and PCR) weekly for the first two months, twice monthly for the next month, then monthly up to six months. Subsequently, monitoring intervals can be lengthened. (See <a href=\"#H3373172918\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest NOT administering presumptive antitrypanosomal therapy for patients at risk for <em>T. cruzi</em> reactivation or donor-derived acute <em>T.</em> <em>cruzi</em> infection (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Presumptive treatment is unlikely to be curative in this setting and carries substantial risk of adverse effects. In addition, establishing the presence of infection is important for long-term management; presumptive treatment would preclude this evaluation. (See <a href=\"#H1793244921\" class=\"local\">'Prevention'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/1\" class=\"nounderline abstract_t\">Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/2\" class=\"nounderline abstract_t\">Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/3\" class=\"nounderline abstract_t\">Martinez-Perez A, Norman FF, Monge-Maillo B, et al. An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients. Expert Rev Anti Infect Ther 2014; 12:357.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/4\" class=\"nounderline abstract_t\">Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas' myocarditis during therapy of Hodgkin's disease. Trop Geogr Med 1991; 43:228.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/5\" class=\"nounderline abstract_t\">Kohl S, Pickering LK, Frankel LS, Yaeger RG. Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. Cancer 1982; 50:827.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/6\" class=\"nounderline abstract_t\">Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, et al. Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg 2006; 100:74.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/7\" class=\"nounderline abstract_t\">Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007; 101:31.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/8\" class=\"nounderline abstract_t\">Sartori AM, Neto JE, Nunes EV, et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. J Infect Dis 2002; 186:872.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/9\" class=\"nounderline abstract_t\">Cordova E, Boschi A, Ambrosioni J, et al. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis 2008; 12:587.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/10\" class=\"nounderline abstract_t\">Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, et al. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009; 9:324.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/11\" class=\"nounderline abstract_t\">Campo M, Phung MK, Ahmed R, et al. A woman with HIV infection, brain abscesses, and eosinophilia. Clin Infect Dis 2010; 50:239.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/12\" class=\"nounderline abstract_t\">Vaidian AK, Weiss LM, Tanowitz HB. Chagas' disease and AIDS. Kinetoplastid Biol Dis 2004; 3:2.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/13\" class=\"nounderline abstract_t\">Ferreira MS, Nishioka Sde A, Silvestre MT, et al. Reactivation of Chagas' disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis 1997; 25:1397.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/14\" class=\"nounderline abstract_t\">Bacal F, Silva CP, Pires PV, et al. Transplantation for Chagas' disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transplant 2010; 24:E29.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/15\" class=\"nounderline abstract_t\">Bocchi EA, Fiorelli A, First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant 2001; 20:637.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/16\" class=\"nounderline abstract_t\">Fiorelli AI, Santos RH, Oliveira JL Jr, et al. Heart transplantation in 107 cases of Chagas' disease. Transplant Proc 2011; 43:220.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/17\" class=\"nounderline abstract_t\">Kransdorf EP, Czer LS, Luthringer DJ, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant 2013; 13:3262.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/18\" class=\"nounderline abstract_t\">Marchiori PE, Alexandre PL, Britto N, et al. Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy. J Heart Lung Transplant 2007; 26:1091.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/19\" class=\"nounderline abstract_t\">Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999; 29:561.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/20\" class=\"nounderline abstract_t\">Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005; 36:123.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/21\" class=\"nounderline abstract_t\">Fiorelli AI, Stolf NA, Honorato R, et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc 2005; 37:2793.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/22\" class=\"nounderline abstract_t\">Campos SV, Strabelli TM, Amato Neto V, et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant 2008; 27:597.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/23\" class=\"nounderline abstract_t\">Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007; 7:1633.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/24\" class=\"nounderline abstract_t\">Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis 2009; 3:e419.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/25\" class=\"nounderline abstract_t\">Gallerano V, Consigli J, Pereyra S, et al. Chagas' disease reactivation with skin symptoms in a patient with kidney transplant. Int J Dermatol 2007; 46:607.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/26\" class=\"nounderline abstract_t\">d'Avila SC, d'Avila AM, Pagliari C, et al. [Erythema nodoso in reactivation of Chagas' disease after cardiac transplantation]. Rev Soc Bras Med Trop 2005; 38:61.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/27\" class=\"nounderline abstract_t\">P&eacute;rez-Molina JA. Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas. Curr Opin Infect Dis 2014; 27:9.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/28\" class=\"nounderline abstract_t\">Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant 2011; 11:672.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/29\" class=\"nounderline abstract_t\">Guiang KM, Cantey P, Montgomery SP, et al. Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management. Transpl Infect Dis 2013; 15:E264.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/30\" class=\"nounderline abstract_t\">Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis 2014; 27:418.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/31\" class=\"nounderline abstract_t\">Pinazo MJ, Miranda B, Rodr&iacute;guez-Villar C, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando) 2011; 25:91.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/32\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:210.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/33\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Chagas disease after organ transplantation--Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:798.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/34\" class=\"nounderline abstract_t\">Chocair PR, Sabbaga E, Amato Neto V, et al. [Kidney transplantation: a new way of transmitting chagas disease]. Rev Inst Med Trop Sao Paulo 1981; 23:280.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/35\" class=\"nounderline abstract_t\">de Arteaga J, Massari PU, Galli B, et al. Renal transplantation and Chagas' disease. Transplant Proc 1992; 24:1900.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/36\" class=\"nounderline abstract_t\">de Faria JB, Alves G. Transmission of Chagas' disease through cadaveric renal transplantation. Transplantation 1993; 56:1583.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/37\" class=\"nounderline abstract_t\">Ferraz AS, Figueiredo JF. Transmission of Chagas' disease through transplanted kidney: occurrence of the acute form of the disease in two recipients from the same donor. Rev Inst Med Trop Sao Paulo 1993; 35:461.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/38\" class=\"nounderline abstract_t\">Figueiredo JF, Martinez R, da Costa JC, et al. Transmission of Chagas disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg 1990; 84:61.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/39\" class=\"nounderline abstract_t\">Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011. Am J Transplant 2013; 13:2418.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/40\" class=\"nounderline abstract_t\">Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48:1534.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/41\" class=\"nounderline abstract_t\">Barc&aacute;n L, Luna C, Clara L, et al. Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transpl 2005; 11:1112.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/42\" class=\"nounderline abstract_t\">Souza FF, Castro-E-Silva O, Marin Neto JA, et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc 2008; 40:875.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on November 04, 2015).</li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-in-the-immunosuppressed-host/abstract/44\" class=\"nounderline abstract_t\">Maldonado C, Albano S, Vettorazzi L, et al. Using polymerase chain reaction in early diagnosis of re-activated Trypanosoma cruzi infection after heart transplantation. J Heart Lung Transplant 2004; 23:1345.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 114195 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3818210673\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H944109389\" id=\"outline-link-H944109389\">INTRODUCTION</a></li><li><a href=\"#H1365939822\" id=\"outline-link-H1365939822\">FORMS OF DISEASE</a><ul><li><a href=\"#H3802398010\" id=\"outline-link-H3802398010\">Reactivation of chronic Chagas in immunosuppressed patients</a><ul><li><a href=\"#H1896463927\" id=\"outline-link-H1896463927\">- Clinical manifestations</a><ul><li><a href=\"#H278374802\" id=\"outline-link-H278374802\">HIV-infected patients</a></li><li><a href=\"#H2546020043\" id=\"outline-link-H2546020043\">Transplant recipients</a></li></ul></li><li><a href=\"#H1592432218\" id=\"outline-link-H1592432218\">- Diagnosis</a></li><li><a href=\"#H1494447060\" id=\"outline-link-H1494447060\">- Monitoring</a></li></ul></li><li><a href=\"#H2323762035\" id=\"outline-link-H2323762035\">Donor-derived acute Chagas in organ transplant recipients</a><ul><li><a href=\"#H3101896265\" id=\"outline-link-H3101896265\">- Clinical manifestations</a></li><li><a href=\"#H3859670968\" id=\"outline-link-H3859670968\">- Diagnosis</a></li><li><a href=\"#H3373172918\" id=\"outline-link-H3373172918\">- Monitoring</a></li></ul></li></ul></li><li><a href=\"#H2256850938\" id=\"outline-link-H2256850938\">TREATMENT AND PREVENTION</a><ul><li><a href=\"#H2407026926\" id=\"outline-link-H2407026926\">Treatment</a></li><li><a href=\"#H1793244921\" id=\"outline-link-H1793244921\">Prevention</a></li></ul></li><li><a href=\"#H654269154\" id=\"outline-link-H654269154\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H3818210673\" id=\"outline-link-H3818210673\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/114195|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/82194\" class=\"graphic graphic_diagnosticimage\">- MRI of reactivated Chagas in the CNS</a></li></ul></li><li><div id=\"ID/114195|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/65745\" class=\"graphic graphic_table\">- Treatment of Chagas disease</a></li><li><a href=\"image.htm?imageKey=ID/54443\" class=\"graphic graphic_table\">- Antitrypanosomal drugs dosing</a></li><li><a href=\"image.htm?imageKey=ID/67193\" class=\"graphic graphic_table\">- Side effects of antitrypanosomal drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-and-early-hiv-infection-treatment\" class=\"medical medical_review\">Acute and early HIV infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">Approach to HIV-infected patients with central nervous system lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">Chagas disease: Acute and congenital Trypanosoma cruzi infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">Chagas disease: Antitrypanosomal drug therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-chronic-trypanosoma-cruzi-infection\" class=\"medical medical_review\">Chagas disease: Chronic Trypanosoma cruzi infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention\" class=\"medical medical_review\">Chagas disease: Epidemiology and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">Chagas gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Chagas heart disease: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">Chagas heart disease: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li></ul></div></div>","javascript":null}